Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report)’s stock price was up 4.4% on Thursday . The stock traded as high as $1.92 and last traded at $1.92. Approximately 9,470 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 30,220 shares. The stock had previously closed at $1.84.
Humacyte Stock Up 3.7 %
The company’s 50 day moving average price is $1.85 and its two-hundred day moving average price is $1.84.
About Humacyte
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- Golden Cross Stocks: Pattern, Examples and Charts
- Battle of the Retailers: Who Comes Out on Top?
- Options Trading – Understanding Strike Price
- HCA Healthcare: Temporary Setbacks, Long-Term Strength
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- MarketBeat Week in Review – 10/28 – 11/1
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
